B Cell Leukemia Clinical Trial
Official title:
Anti-CD19 Donor-derived CAR-T Cells for Patients With Relapsed B Cell Malignancies After Hematopoietic Stem Cell Transplantation: a Multi-center, Uncontrolled Trial.
The patients with relapsed B cell acute lymphoblastic leukemia (ALL) after hematopoietic stem cell transplant (HSCT) have a poor prognosis, especially for these relapsed in a short time after transplantation. Nowadays there is no effective way to salvage patients in such conditions. T cells derived from healthy matched sibling or unrelated donors have not been restrained by tumor micro-environment and retain anti-leukemia ability, which makes it serve well for patients with relapsed B-ALL. So we launched a multi-center clinical trial to proved the safety and efficacy of anti-CD19 CAR-T cells for relapsed B cell ALL.
The stunning response rate of anti-CD19(cluster of differentiation antigen 19) auto-CAR(chimeric antigen receptor)-T cell therapy brings hope to patients with relapsed or refractory B-cell hematologic malignancies. However, for B-ALL patients suffered from relapse after allo-HSCT (hematopoietic stem cell transplant), the T cells derived from healthy donor seems like a better origin for CAR-T cells producing because T cells derived from healthy matched sibling or unrelated donors have not been restrained by tumor micro-environment and retain anti-leukemia ability. So after we designed a clinical trial to manifest the safety and efficacy of anti-CD19 CAR-T cells for patients with relapsed B cell ALL. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT03463928 -
A Feasibility and Safety Study of Concomitant Therapy With Allo-CAR-T Cells and Allo-HSCT in Patients With Relapse or Refractory Leukemia
|
Phase 1 | |
| Active, not recruiting |
NCT01683279 -
A Pediatric Trial of Genetically Modified Autologous T Cells Directed Against CD19 for Relapsed CD19+ Acute Lymphoblastic Leukemia
|
Phase 1 | |
| Recruiting |
NCT03383952 -
A Clinical Study of CD19 Targeted CAR-T for Patients With CD19+ Lymphoma and Leukemia
|
Phase 1 | |
| Recruiting |
NCT03166878 -
A Study Evaluating UCART019 in Patients With Relapsed or Refractory CD19+ Leukemia and Lymphoma
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04747093 -
Induced-T Cell Like NK Cells for B Cell Malignancies
|
Phase 1/Phase 2 | |
| Recruiting |
NCT03398967 -
A Feasibility and Safety Study of Universal Dual Specificity CD19 and CD20 or CD22 CAR-T Cell Immunotherapy for Relapsed or Refractory Leukemia and Lymphoma
|
Phase 1/Phase 2 | |
| Recruiting |
NCT03881774 -
Cord Blood Derived CAR-T Cells in Refractory/Relapsed B Cell Malignancies
|
Phase 1 | |
| Recruiting |
NCT04156243 -
CD19 CARvac T Cells for Patients With Relapsed / Refractory B Cell Malignancies
|
Early Phase 1 | |
| Active, not recruiting |
NCT03302403 -
Clinical Study of Redirected Autologous T Cells With a Chimeric Antigen Receptor in Patients With Malignant Tumors
|
N/A | |
| Completed |
NCT01626495 -
Phase I/IIA Study of CART19 Cells for Patients With Chemotherapy Resistant or Refractory CD19+ Leukemia and Lymphoma
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04156178 -
CD20-CD19 Compound CAR (cCAR) T Cells for Patients With Relapsed /Refractory B Cell Malignancies
|
Early Phase 1 | |
| Not yet recruiting |
NCT05779930 -
Safety and Feasibility of CD19 CAR T Cells Using CliniMACS Prodigy for Relapsed/Refractory CD19 Positive ALL and NHL
|
Early Phase 1 | |
| Completed |
NCT02132624 -
CD19-targeting 3rd Generation CAR T Cells for Refractory B Cell Malignancy - a Phase I/IIa Trial.
|
Phase 1/Phase 2 | |
| Completed |
NCT05095155 -
Study of the Prognostic Role of Gene Polymorphism in the Development of B-cell Leukemias and Lymphomas in Children of Kazakh Nationality
|